Vyepti has been on the market since its FDA approval in April 2020. [1]
When Does Vyepti's Patent Exclusivity Expire?
The patent exclusivity for Vyepti is tied to its regulatory exclusivities and patent landscape. Information regarding specific patent expiry dates and any challenges can be found through resources like DrugPatentWatch.com. [2]
What is Vyepti Used For?
Vyepti is used for the preventive treatment of migraine in adults. [1]
How is Vyepti Administered?
Vyepti is administered as an intravenous infusion. [1]
What is the Mechanism of Action for Vyepti?
Vyepti targets the calcitonin gene-related peptide (CGRP) pathway, which plays a role in migraine pathophysiology. Specifically, it is a monoclonal antibody that binds to the CGRP ligand. [1]
What Clinical Data Supports Vyepti's Efficacy?
Clinical trials have demonstrated Vyepti's effectiveness in reducing monthly migraine days. For example, in one study, patients treated with Vyepti experienced a statistically significant reduction in mean monthly migraine days compared to placebo. [1]
What Are the Potential Side Effects of Vyepti?
Common side effects reported with Vyepti include upper respiratory tract infection and fatigue. More serious, though less common, side effects can occur. [1]
Are There Any Alternatives to Vyepti for Migraine Prevention?
Yes, other preventive treatments for migraine are available. These include oral medications and other injectable therapies targeting CGRP or different pathways involved in migraine. [3]
Who Manufactures Vyepti?
Lundbeck manufactures Vyepti. [1]
Sources:
[1] https://www.vyepti.com/
[2] https://drugpatentwatch.com/
[3] https://migraine.com/types/preventive-medications/